User profiles for Pantep Angchaisuksiri
 | Pantep AngchaisuksiriProfessor of Medicine, Mahidol University Verified email at mahidol.ac.th Cited by 7816 |
Thrombosis: a major contributor to global disease burden
GE Raskob, P Angchaisuksiri, AN Blanco… - … , and vascular biology, 2014 - Am Heart Assoc
Background— Thrombosis is the common pathology underlying ischemic heart disease,
ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study …
ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study …
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-…
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-…
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
…, F Ajauro, T Alcindor, P Angchaisuksiri… - The Lancet …, 2022 - thelancet.com
The International Initiative on Thrombosis and Cancer is an independent academic working
group of experts aimed at establishing global consensus for the treatment and prophylaxis of …
group of experts aimed at establishing global consensus for the treatment and prophylaxis of …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer.
These patients are at a high risk of VTE recurrence and bleeding during anticoagulant …
These patients are at a high risk of VTE recurrence and bleeding during anticoagulant …
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of …
Background: COVID-19–related acute illness is associated with an increased risk of venous
thromboembolism (VTE). Objective: These evidence-based guidelines from the American …
thromboembolism (VTE). Objective: These evidence-based guidelines from the American …
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase …
…, S Penco, A Vaya, P Angchaisuksiri… - European journal of …, 2013 - Springer
Genetic and environmental factors interact in determining the risk of venous thromboembolism
(VTE). The risk associated with the polymorphic variants G1691A of factor V (Factor V …
(VTE). The risk associated with the polymorphic variants G1691A of factor V (Factor V …
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
…, K Knobe, FA Karim, P Angchaisuksiri… - Blood, The Journal …, 2014 - ashpublications.org
This multinational, randomized, single-blind trial investigated the safety and efficacy of
nonacog beta pegol, a recombinant glycoPEGylated factor IX (FIX) with extended half-life, in 74 …
nonacog beta pegol, a recombinant glycoPEGylated factor IX (FIX) with extended half-life, in 74 …
[HTML][HTML] Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry
S Haas, H Ten Cate, G Accetta, P Angchaisuksiri… - PloS one, 2016 - journals.plos.org
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines
recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke …
recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke …
[HTML][HTML] Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis
…, A Phuphuakrat, P Niparuck, P Angchaisuksiri - Thrombosis journal, 2020 - Springer
Background Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, the
incidence of thromboembolism has been increasingly reported. The aim of this systematic …
incidence of thromboembolism has been increasingly reported. The aim of this systematic …
[HTML][HTML] Phase 3 trial of concizumab in hemophilia with inhibitors
Background Concizumab is an anti–tissue factor pathway inhibitor monoclonal antibody
designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A …
designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A …